Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in primary hypercholesterolemia with coronary heart disease
2005-004848-31Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2006
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Vytorin and simvastatin in hypercholesterolemia and coronary arteriosclerosis (2 arms), sponsored by Merck & Co. Primary endpoint: Change in LDL-C concentration at endpoint after 6 weeks. Started Mar 2006; status: completed.
02
Drugs
Vytorinsimvastatin
03
Conditions
hypercholesterolemiacoronary arteriosclerosis
Beyond the preview
Go deeper on 2005-004848-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004848-31.